AlphaYou
Overview
No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.
Key stats
Aug 23- Open
- $228.88
- 52-wk high
- $495.55
- High
- $238.97
- 52-wk low
- $197.81
- Low
- $228.34
- Prev close
- $229.30
Smart money
Earnings
Earnings came in 16.0% below what analysts expected.
Financials
What it sold, what it cost, what was left.
Sep 2025Dec 2025Mar 2026Jun 2026
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.25B | $1.10B | $1.17B | $1.29B |
| Cost of what it sold | $197.2M | $267.7M | $211.1M | $298.3M |
| Gross profit | $1.05B | $829.3M | $956.1M | $992.7M |
| What it spent | ||||
| Research and development | $358.8M | $372.2M | $364.9M | $413.1M |
| Sales and admin | $322.1M | $325.4M | $322.6M | $347.9M |
| Total operating expenses | $683.8M | $697.6M | $687.4M | $761.2M |
| What was left | ||||
| Operating profit | $368.0M | $131.7M | $268.6M | $231.4M |
| Interest on debt | $44.4M | $129.3M | $69.3M | $82.1M |
| Profit before tax | $239.0M | $161.1M | $221.7M | $177.8M |
| Tax | -$12.1M | -$25.3M | -$15.7M | $13.3M |
| Net profit | $251.1M | $186.4M | $206.0M | $164.5M |
| EBITDA | $297.2M | $304.0M | $304.5M | $244.7M |
Technicals
Price structure
This stock is under pressure.
Trend
Under pressure
35 / 100
RSI 14
60balanced
20D volatility
132%annualized
52-week range
$197.81$495.55
20D support
News
What the news says
32 articles · 7 days
Coverage is bearish
Tone of tracked coverage
(NASDAQ: ALNY): Investigation Launched Into Alnylam Pharmaceuticals, Inc. by Kessler Topaz Meltzer & Check, LLP
BearishAug 21Silvant Capital Management LLC Takes $5.46 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY
Leans bullishAug 21ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors E
BearishAug 20
